Nanoviricides Inc (AMEX:NNVC) Stock News, Headlines & Updates
Nanoviricides Inc Stock News from GuruFocus
- 1
- 2
- 3
Feb 15, 2024
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
ACCESSWIRE • 7:00am
Feb 12, 2024
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
ACCESSWIRE • 3:00pm
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
ACCESSWIRE • 3:00pm
Jan 04, 2024
NanoViricides to Present at the Biotech Showcase in San Fransisco
ACCESSWIRE • 7:00am
Nov 28, 2023
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
ACCESSWIRE • 7:00am
Nov 15, 2023
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
ACCESSWIRE • 7:00am
Oct 16, 2023
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
ACCESSWIRE • 7:00am
Oct 12, 2023
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
ACCESSWIRE • 7:00am
Aug 21, 2023
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
ACCESSWIRE • 7:00am
Jul 11, 2023
Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
ACCESSWIRE • 7:00am
Jul 06, 2023
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
ACCESSWIRE • 7:00am
Jun 29, 2023
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
ACN Newswire • 7:00am
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
ACCESSWIRE • 7:00am
Oct 12, 2021
NanoViricides: There Is More to Come
Ishan Majumdar • 1:56am
Sep 23, 2021
NanoViricides: Why Has the Stock Doubled?
Ishan Majumdar • 7:35am
May 17, 2021
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND
ACCESSWIRE • 7:00am
Mar 09, 2021
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application
ACCESSWIRE • 6:59am
Mar 02, 2021
Feb 17, 2021
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
ACCESSWIRE • 7:00am
Feb 08, 2021
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies
ACCESSWIRE • 7:00am
Nov 19, 2020
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
ACCESSWIRE • 7:00am
Nov 17, 2020
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress
ACCESSWIRE • 7:00am
Nov 11, 2020
NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19
ACCESSWIRE • 7:00am
NanoViricides: One Step at a Time
Ishan Majumdar • 9:55am
Oct 15, 2020
NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program
ACCESSWIRE • 7:00am
Sep 16, 2020
NanoViricides to Use Gilead Sciences' Remdesivir in Potential Covid Therapy
Ishan Majumdar • 1:36pm
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19
ACCESSWIRE • 7:00am
Sep 08, 2020
NanoViricides, Inc. Investors Who Purchased NNVC Securities Between January 23, 2020 and July 13, 2020 And Suffered Significant Losses Encouraged To Contact Kehoe Law Firm, P.C.
PRNewswire • 11:03am
Sep 04, 2020
NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference
ACCESSWIRE • 7:00am
Sep 03, 2020
NanoViricides: Ready for the IND Application for a Novel Covid-19 Drug
Ishan Majumdar • 4:39pm
Sep 02, 2020
NanoViricides to Present COVID-19 Drug Update at The LD 500 Virtual Conference
ACCESSWIRE • 11:00am
Jul 21, 2020
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020
ACCESSWIRE • 7:00am
Jul 16, 2020
NanoViricides, Inc. Investors Who Purchased NNVC Securities After January 2020 And Suffered Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
Marketwired • 11:00am
Jul 13, 2020
NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock
ACCESSWIRE • 7:00am
Jul 09, 2020
NanoViricides Prices $10.0 Million Underwritten Public Offering of Common Stock
ACCESSWIRE • 7:00am
Nanoviricides Commences Underwritten Public Offering of Common Stock
ACCESSWIRE • 7:00pm
Jul 08, 2020
Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides' SARS-CoV-2 Therapeutics Program
ACCESSWIRE • 7:00am
Jun 30, 2020
NanoViricides Announces Addition to Russell Microcap(R) Index
ACCESSWIRE • 7:00am
Jun 25, 2020
NanoViricides: Sufficient Funding for Covid-19 Research
Ishan Majumdar • 9:05am
Jun 23, 2020
- 1
- 2
- 3
Show
Entries
Headlines
Total 0- 1
No recent news
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers